Updated:
Cerus Advisors
Cerus Advisors was established in 2015 by Marios Fotiadis and Kleanthis G. Xanthopoulos. The principals built their capital base through prior roles at...
Cerus Advisors
Cerus Advisors was established in 2015 by Marios Fotiadis and Kleanthis G. Xanthopoulos. The principals built their capital base through prior roles at Enterprise Partners Venture Capital and Cowen Capital Partners plus company formations including Anadys Pharmaceuticals. The firm allocates across private equity, real estate, private credit, hedge funds and direct co-investments or SPVs. Confirmed positions include board roles at Senté Inc., IRRAS AB, Shoreline Biosciences and DalCor Pharmaceuticals. Geographic reach spans North America, Europe, the Middle East, Africa, Asia and South America. Stage focus includes buyouts, growth equity and venture capital. Team size and total deployment remain undisclosed. Marios Fotiadis also serves as CEO of Vandel Group LLC and holds a directorship at Bacara Holdings. Kleanthis G. Xanthopoulos chairs Regulus Therapeutics and serves on boards including Malin Corporation. No operational events from the last 24 months appear in available records. Cerus Advisors maintains a hybrid structure that combines internal principal capital with external syndication alongside peer family offices and institutions. This model allows selective co-investment without reliance on third-party fund commitments.
General information
Firm type
Single Family Office
Year founded
2015
AUM
Undisclosed
Location
Region
Asia
Country
United Arab Emirates
City
Dubai
Corporate office
Dubai, United Arab Emirates
Principals
Marios Fotiadis
Chairman and Managing Partner
Kleanthis G. Xanthopoulos
Managing General Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Cerus Advisors?
Marios Fotiadis serves as Chairman and Managing Partner. Kleanthis G. Xanthopoulos serves as Managing General Partner. Both principals participate directly in sourcing and board oversight of portfolio holdings.
How does Cerus Advisors source proprietary deal flow?
The firm sources and syndicates deals with peer offices and institutional partners worldwide. Relationships formed through prior venture capital roles and board positions at companies such as Regulus Therapeutics support access to opportunities.
Is Cerus Advisors structured as a single family office or does it operate more like a venture firm?
Cerus Advisors operates as a single-family office. It deploys principals’ capital directly while also participating in co-investments and syndications alongside external partners.
Does Cerus Advisors participate in fund commitments or only direct deals?
The firm uses multiple vehicles including fund-of-funds commitments, direct co-investments or SPVs, private equity and real estate holdings. No single structure dominates disclosed activity.
What investment stages does Cerus Advisors typically target?
Stage coverage includes buyouts, growth equity and venture capital. Portfolio involvement spans early company formation through later-stage healthcare and property assets.
Where does the underlying wealth come from?
Wealth originates from serial biotechnology and healthcare ventures led by the principals, including prior exits such as Anadys Pharmaceuticals to Roche.
What is Cerus Advisors known posture on co-investments alongside external GPs?
The firm regularly syndicates deals with peer offices and institutional partners. Board seats at Senté Inc. and IRRAS AB illustrate direct involvement alongside other capital providers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: